KalVista Pharmaceuticals, Inc. (KALV)

KalVista Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is May - April.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	486	291	312	607	195	397
Market Cap Growth	178.11%	-6.71%	-48.53%	211.76%	-50.92%	281.96%
Enterprise Value	416	149	153	363	128	296
PE Ratio	-	-3.14	-3.79	-13.12	-6.69	-19.06
PS Ratio	-	-	-	-	15.34	24.60
PB Ratio	5.48	1.81	1.69	2.36	2.33	4.10
P/FCF Ratio	-5.61	-3.81	-3.95	-20.06	-4.32	-10.59
P/OCF Ratio	-5.63	-3.87	-4.00	-20.12	-4.34	-10.91
EV/Sales Ratio	-	-	-	-	10.09	18.35
EV/EBITDA Ratio	-4.43	-1.62	-1.88	-7.96	-4.46	-14.57
EV/EBIT Ratio	-4.39	-1.61	-1.86	-7.85	-4.38	-14.30
EV/FCF Ratio	-4.90	-1.95	-1.94	-12.00	-2.84	-7.90
Debt / Equity Ratio	0.07	0.04	0.04	0.02	0.01	-
Debt / EBITDA Ratio	-0.06	-0.08	-0.09	-0.11	-0.04	-
Debt / FCF Ratio	-0.06	-0.09	-0.09	-0.17	-0.02	-
Quick Ratio	3.95	9.94	14.36	25.47	8.77	5.58
Current Ratio	5.44	11.46	16.73	27.04	11.49	6.40
Asset Turnover	0	0	0	0	0.12	0.15
Return on Equity (ROE)	-86.10%	-56.80%	-38.10%	-40.60%	-31.20%	-24.90%
Return on Assets (ROA)	-72.70%	-50.80%	-35.30%	-37.20%	-27.20%	-19.10%
Return on Capital (ROIC)	-130.45%	-65.93%	-50.24%	-22.09%	-47.79%	-30.83%
Earnings Yield	-22.30%	-31.88%	-26.35%	-7.62%	-14.95%	-5.25%
FCF Yield	-20.01%	-26.23%	-25.31%	-4.98%	-23.13%	-9.44%
Buyback Yield / Dilution	-22.79%	-13.97%	-28.17%	-7.58%	-17.69%	-46.11%
Total Shareholder Return	-22.79%	-13.97%	-28.17%	-7.58%	-17.69%	-46.11%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).